Femasys (FEMY) Convertible Debt (2023 - 2025)

Femasys' (FEMY) quarterly Convertible Debt came in at $3.2 million in Q4 2025, down 37.28% quarter-over-quarter from $5.1 million in Q3 2024.

Analysis

Femasys (FEMY) Convertible Debt (2023 - 2025) Analysis & Trends

Femasys (FEMY) has reported Convertible Debt for 3 consecutive years, with $3.2 million the latest figure, recorded in Q4 2025.

For the quarter ending Q4 2025, Convertible Debt changed N/A year-over-year to $3.2 million; the trailing twelve-month figure through Dec 2025 stood at $3.2 million (changed N/A YoY), and the FY2025 full-year result was $3.2 million, changed N/A from the prior year.
Convertible Debt eased to $3.2 million in Q4 2025 per FEMY's latest filing, from $5.1 million in the prior quarter.
Across five years, Convertible Debt topped out at $5.1 million in Q3 2024 and bottomed at $3.2 million in Q4 2025.
Historically, Convertible Debt has averaged $4.3 million across 3 years, with a median of $4.5 million in 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	187.42 Bn	182.47 Bn	7.27 Bn
2	Intuitive Surgical	129.78 Bn	124.69 Bn	1.96 Bn
3	Medtronic	120.53 Bn	112.33 Bn	6.34 Bn
4	Stryker	116.28 Bn	112.80 Bn	4.50 Bn
5	Boston Scientific	69.29 Bn	68.99 Bn	3.85 Bn
6	Edwards Lifesciences	51.83 Bn	47.68 Bn	1.35 Bn
7	Alcon	34.36 Bn	32.91 Bn	1.68 Bn
8	Dexcom	33.17 Bn	31.23 Bn	830.00 Mn
9	Steris	21.90 Bn	21.43 Bn	684.20 Mn
10	Femasys	9.01 Mn	7.57 Mn	189,391.00

Historic Data

Download Data